Marieke Kuijjer

Marieke Kuijjer

Research Fellow
This email address is being protected from spambots. You need JavaScript enabled to view it.

 

Research

My research interests focus around integration of high-throughput 'omics data to better understand disruption of biological processes in difficult to treat cancers. I am currently working on developing computational methods to identify nerw treatment options for cancer patients.

 

Biography

Ph.D., Cancer Genomics, Leiden University Medical Center (2013)
M.Sc. Biomedical Sciences, Leiden University (2008)
B.Sc. Biomedical Sciences, Leiden University (2007)

 

Select Publication

Tumor-infiltrating macrophages are associated with metastasis suppression in high-grade osteosarcoma: a rationale for treatment with macrophage activating agents. Buddingh EP*, Kuijjer ML*, Duim RA, Bürger H, Agelopoulos K, Myklebost O, Serra M, Mertens F, Hogendoorn PC, Lankester AC, Cleton-Jansen AM. Clin Cancer Res. 2011 Apr 15;17(8):2110-9. *Shared first authorship

 

mRNA expression profiles of primary high-grade central osteosarcoma are preserved in cell lines and xenografts. Kuijjer ML, Namløs HM, Hauben EI, Machado I, Kresse SH, Serra M, Llombart-Bosch A, Hogendoorn PC, Meza-Zepeda LA, Myklebost O, Cleton-Jansen AM. BMC Med Genomics. 2011 Sep 20;4:66.

 

Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome. Pansuriya TC, van Eijk R, d'Adamo P, van Ruler MA, Kuijjer ML, Oosting J, Cleton-Jansen AM, van Oosterwijk JG, Verbeke SL, Meijer D, van Wezel T, Nord KH, Sangiorgi L, Toker B, Liegl-Atzwanger B, San-Julian M, Sciot R, Limaye N, Kindblom LG, Daugaard S, Godfraind C, Boon LM, Vikkula M, Kurek KC, Szuhai K, French PJ, Bovée JV. Nat Genet. 2011 Nov 6;43(12):1256-61.

 

Identification of osteosarcoma driver genes by integrative analysis of copy number and gene expression data. Kuijjer ML, Rydbeck H, Kresse SH, Buddingh EP, Lid AB, Roelofs H, Bürger H, Myklebost O, Hogendoorn PC, Meza-Zepeda LA, Cleton-Jansen AM. Genes Chromosomes Cancer. 2012 Jul;51(7):696-706.

 

Alternate splicing of the p53 inhibitor HDMX offers a superior prognostic biomarker than p53 mutation in human cancer. Lenos K, Grawenda AM, Lodder K, Kuijjer ML, Teunisse AF, Repapi E, Grochola LF, Bartel F, Hogendoorn PC, Wuerl P, Taubert H, Cleton-Jansen AM, Bond GL, Jochemsen AG. Cancer Res. 2012 Aug 15;72(16):4074-84.

 

The activities of Smad and Gli mediated signalling pathways in high-grade conventional osteosarcoma. Mohseny AB, Cai Y, Kuijjer ML, Xiao W, van den Akker B, de Andrea CE, Jacobs R, ten Dijke P, Hogendoorn PC, Cleton-Jansen AM. Eur J Cancer. 2012 Dec;48(18):3429-38.

 

Modulation of the osteosarcoma expression phenotype by microRNAs. Namløs HM, Meza-Zepeda LA, Barøy T, Østensen IH, Kresse SH, Kuijjer ML, Serra M, Bürger H, Cleton-Jansen AM, Myklebost O. PLoS One. 2012;7(10):e48086.

 

Genome-wide analyses on high-grade osteosarcoma: making sense of a genomically most unstable tumor. Kuijjer ML, Hogendoorn PC, Cleton-Jansen AM. Int J Cancer. 2013 Dec 1;133(11):2512-21.

 

IR/IGF1R signaling as potential target for treatment of high-grade osteosarcoma. Kuijjer ML, Peterse EF, van den Akker BE, Briaire-de Bruijn IH, Serra M, Meza-Zepeda LA, Myklebost O, Hassan AB, Hogendoorn PC, Cleton-Jansen AM. BMC Cancer. 2013 May 20;13:245.

 

Tumor-infiltrating CD14-positive myeloid cells and CD8-positive T-cells prolong survival in patients with cervical carcinoma. de Vos van Steenwijk PJ, Ramwadhdoebe TH, Goedemans R, Doorduijn EM, van Ham JJ, Gorter A, van Hall T, Kuijjer ML, van Poelgeest MI, van der Burg SH, Jordanova ES. Int J Cancer. 2013 Dec 15;133(12):2884-94.

 

Immune response to RB1-regulated senescence limits radiation-induced osteosarcoma formation. Kansara M, Leong HS, Lin DM, Popkiss S, Pang P, Garsed DW, Walkley CR, Cullinane C, Ellul J, Haynes NM, Hicks R, Kuijjer ML, Cleton-Jansen AM, Hinds PW, Smyth MJ, Thomas DM. J Clin Invest. 2013 Dec;123(12):5351-60.

 

Kinome and mRNA expression profiling of high-grade osteosarcoma cell lines implies Akt signaling as possible target for therapy. Kuijjer ML, van den Akker BE, Hilhorst R, Mommersteeg M, Buddingh EP, Serra M, Bürger H, Hogendoorn PC, Cleton-Jansen AM. BMC Med Genomics. 2014 Jan 21;7:4.

 

Macrophages inhibit human osteosarcoma cell growth after activation with the bacterial cell wall derivative liposomal muramyl tripeptide in combination with interferon-γ. Pahl JH, Kwappenberg KM, Varypataki EM, Santos SJ, Kuijjer ML, Mohamed S, Wijnen JT, van Tol MJ, Cleton-Jansen AM, Egeler RM, Jiskoot W, Lankester AC, Schilham MW. J Exp Clin Cancer Res. 2014 Mar 10;33:27.


 

Keywords

high-throughput, 'omics